ABL1 and acute lymphoblastic leukemia: Studies to evaluate the efficacy of imatinib—an ABL tyrosine kinase inhibitor (TKI)—in combination with intensive chemotherapy in children with Ph+ ALL have reported dramatic improvements in overall survival17–19.